The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential competitor to Soleno’s fast-selling Vykat.

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a framework that could support a clearance if upcoming study results are ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

As launches get increasingly competitive, with the potential for multiple therapeutics to target the same indications, therapeutics developers must take advantage of every opportunity to maximize ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...